Gastrointestinal effects of COX-2 inhibitors

Expert Opinion on Investigational Drugs

Volumn 8, Issue 7, 1999, Pages 963-971

  Jackson, L M ^a   Hawkey, C J ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

COX 1; COX 2; Cyclooxygenase; NSAIDs; Prostaglandins; Ulcers

Indexed keywords

ACETYLSALICYLIC ACID; CELOXICOB; CORTICOSTEROID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; IBUPROFEN; MELOXICAM; NABUMETONE; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; ROFEXICOB; UNCLASSIFIED DRUG; WARFARIN;

CLINICAL TRIAL; COLON CANCER; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG SYNTHESIS; DUODENUM MUCOSA; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT FUNCTION; HUMAN; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; STOMACH MUCOSA; STOMACH ULCER;

EID: 0032805977     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.8.7.963     Document Type: Review

References (76)